PD1039 - RANDOMIZED CONTROLLED TRIAL COMPARING THE SHORT-TERM OUTCOMES OF ENHANCED RECOVERY AFTER SURGERY AND CONVENTIONAL CARE IN LAPAROSCOPIC DISTAL GASTRECTOMY (GISSG1901)
PD1039
RANDOMIZED CONTROLLED TRIAL COMPARING THE SHORT-TERM OUTCOMES OF ENHANCED RECOVERY AFTER SURGERY AND CONVENTIONAL CARE IN LAPAROSCOPIC DISTAL GASTRECTOMY (GISSG1901)
Y. Tian1, Y. Zhou1,*, S. Cao1
1the affiliated hospital of qingdao university, Qingdao, China
Rationale: Currently, the ERAS program is broadly applied in surgical areas. Although several benefits of LDG with the ERAS program have been covered, high-level evidence is still limited, specifically in advanced gastric cancer.
Methods: The present study was designed as a randomized, multicenter, unblinded trial. The enrollment criteria included histologically confirmed cT2-4aN0-3M0 gastric adenocarcinoma. Postoperative complications, mortality, readmission, medical costs, recovery, and laboratory outcomes were compared between the ERAS and conventional groups.
Results: Between April 2019 and May 2020, 400 consecutive patients who met the enrollment criteria were enrolled. The conventional group had a significantly longer allowed day of discharge and postoperative hospital stay; a longer time to first flatus, liquid intake and ambulation; and higher medical costs than the ERAS group. Additionally, patients in the ERAS group were more likely to initiate adjuvant chemotherapy earlier. Regarding laboratory outcomes, the procalcitonin and C-reactive protein levels on postoperative day 3 were significantly lower and the hemoglobin levels on postoperative day 5 were significantly higher in the ERAS group than in the conventional group.
Conclusion: The ERAS program provides a faster recovery, a shorter postoperative hospitalization length, and lower medical costs after LDG without increasing complication and readmission rates. Moreover, enhanced recovery in the ERAS group enables early initiation of adjuvant chemotherapy.
Disclosure of Interest: None declared